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Metabolic syndrome (MS) is associated with an
increased risk of type 2 diabetes mellitus and
cardiovascular diseases. There is no recognized
method to manage MS. Many physicians treat the
individual characteristics of MS (high blood pressure,
high triglycerides, and so on) instead of the syndrome
as a whole, placing particular emphasis on those
components that are easily amenable to drug
treatment. However, regular physical exercise and a
healthy diet have been demonstrated to improve the
health of a number of populations, but few studies
have assessed their effects in patients with MS. A
meta-analysis by Yamaoka and Tango in BMC Medicine
found that a lifestyle change program (dietary
counseling and encouragement to exercise) resulted
in improvements in components of MS and in
reducing the proportion of patients with MS. The
effects may not be impressive in absolute terms, but
the data should be interpreted with the
heterogeneity of the included studies in mind.
Because of the many adverse side effects of the drugs
used to correct individual aspects of MS, this meta-
analysis provides strong evidence that lifestyle
changes must be the first-line approach to
manage MS.
See related article http://www.biomedcentral.com/
1741-7015/10/138/abstract
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Commentary
Metabolic syndrome (MS), defined as a cluster of biolo-
gical and physiological characteristics, is associated with
an increased risk of type 2 diabetes mellitus, cardiovas-
cular disease (CVD), and all-cause mortality [1,2].
Several definitions of MS have been given, depending
on the respective fields of specialty of the experts (cardi-
ology, diabetes, obesity, and so on). According to the
American Heart Association [1], MS is diagnosed when
any three of the following criteria are associated: waist
circumference >102 cm in men and >88 cm in women;
triglycerides >150 mg/dl; high-density lipoprotein (HDL)
cholesterol <40 mg/dl in men and <50 mg/dl in women;
systolic blood pressure >130 mmHg, diastolic blood
pressure >85 mmHg, or current use of antihypertensive
medication; and fasting glucose >100 mg/dl or current
drug treatment for elevated blood glucose.
The clinical management of MS is difficult because
there is no recognized method to prevent or improve the
whole syndrome, the background of which is essentially
insulin resistance [3]. Therefore, many physicians,
depending on their own medical subspecialty, treat one
particular characteristic of MS (high blood pressure, high
blood glucose, and so on) instead of the syndrome as a
whole. However, one of the characteristics of MS is gen-
erally more degraded than the others in most patients
(overweight, high triglycerides, and so on), and it is this
one that patients usually wish to have corrected.
Thus, most physicians treat each component of MS
separately, laying particular emphasis on those compo-
nents that are easily amenable to drug treatment. In
fact, it is easier to prescribe a drug to lower blood pres-
sure, blood glucose or triglycerides rather than initiating
a long-term strategy to change people’s lifestyle (exercise
more, eat better) in the hope that they will ultimately
lose weight and tend to have lower blood pressure,
blood glucose and triglycerides.Correspondence: michel.delorgeril@ujf-grenoble.fr
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This is a critical issue because it is still not clear
whether type 2 diabetes and CVD ultimately result from
a deleterious lifestyle or from the specific abnormalities
that characterize MS. In other words: is it the lack of
physical exercise that is harmful, or a low HDL level?
Recent data regarding the use of drugs to raise HDL
levels suggest that a marked increase in HDL does not
result in significant health benefits, and that it may be
more important to correct the lifestyle; that is, more
skeletal muscle activity associated with more physical
exercise rather than artificially increasing HDL using a
drug [4-6].
In addition, there is still controversy regarding the
best diet to reduce the risk of type 2 diabetes and to
prevent or improve MS [7-12].
As a consequence, many physicians think that the first
priority to protect their patients is to help them stop
smoking and lower their blood cholesterol (usually with a
statin), hoping that this approach will reduce the risk of
CVD complications. However, both smoking cessation
[13,14] and use of statins - causing a decrease in physical
activity because of their toxicity on skeletal muscle
[15,16]- can lead to weight gain, deterioration of some
MS characteristics and increase the risk of new-onset
type 2 diabetes [17,18].
It is only on reconsideration that some physicians may
try to improve their patient’s diet and encourage them to
exercise more. At that time, as smoking cessation and
lower cholesterol levels due to use of a statin may have
considerably improved their risk factor status, patients
might be unwilling to further change their lifestyle. Also,
many of them may be reluctant to exercise because of
the toxic effects of statins on their muscles. As a conse-
quence, proactive physicians prescribe drugs to lower
blood pressure, blood glucose and triglycerides to further
improve the risk factor status of their patients, and many
patients inevitably develop the many adverse effects of
these drugs [19-22], in particular increased insulin resis-
tance. This is definitely a vicious circle, and unfortunately
a realistic description of what happens in daily medical
practice.
And yet, regular physical exercise and a healthy diet
have been unequivocally demonstrated to improve the
health of a number of populations [23-27]. However, few
studies have assessed their effects in individuals with MS
[28-32].
In this context, the systematic review and meta-analysis
performed by Yamaoka and Tango, examining the effects
of lifestyle changes on MS, is welcome [33]. They have
identified eight randomized controlled trials and included
them in a meta-analysis. They found that a lifestyle change
program (essentially dietary counseling and encourage-
ment to exercise more) resulted in significant improve-
ments in most components of MS and in reducing the
proportion of patients with MS in comparison to conven-
tional approaches [33].
The effects may not be impressive in absolute terms, but
the data should be interpreted with the heterogeneity of
the included studies in mind. In fact, variability is quite
wide in terms of study duration and the types of lifestyle
changes. For instance, some investigators used either the
DASH (’Dietary Approaches to Stop Hypertension’) or the
Mediterranean diet, whereas others used low-fat diets.
The studied populations also are a source of heteroge-
neity. Some studies were conducted in Europe, either
Northern Europe (UK and Finland) or Southern Europe
(Italy and Spain), and others in the USA and in Iran. In
fact, it is likely that the traditional lifestyles in these var-
ious parts of the world and the expected responses of the
studied populations to any intervention will be different.
Finally, there was no attempt in this meta-analysis to
adjust for the drugs used in these highly diverse popula-
tions. As discussed above, drugs remain the preferred
approach of many physicians in most European countries
and in the USA to improve or suppress the abnormalities
associated with MS. This factor may have been a major
confounder in some of the included trials.
Despite these limitations, and also because of the
many adverse side effects of the drugs used to correct
some aspects of MS, as the authors conclude, this meta-
analysis provides strong evidence that long-term lifestyle
changes must be the first-line approach to reduce the
prevalence of MS and of its complications.
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